Navigation Links
Intarcia Therapeutics, Inc. Announces Appointment of Kenneth Luskey, M.D. as Vice President, Clinical Research
Date:9/9/2008

HAYWARD, Calif., Sept. 9 /PRNewswire/ -- Intarcia Therapeutics, Inc. today announced the appointment of Kenneth Luskey, M.D. to the newly created position of Vice President, Clinical Research reporting to K. Alice Leung, the Company's CEO. In his new role, Dr. Luskey will lead the clinical development of Intarcia's proprietary drug development programs including Omega DUROS(R) therapy for hepatitis C and ITCA 650 for the treatment of type 2 diabetes.

(Logo: http://www.newscom.com/cgi-bin/prnh/20050301/SFTU126LOGO)

Dr. Luskey has extensive experience in endocrinology and metabolism research, as well as in drug development. He spent more than 13 years in academic medicine prior to holding leadership positions with several biopharmaceutical companies where he directed the development of new therapies for the treatment of diabetes. Dr. Luskey began his career at the National Institutes of Health before completing a fellowship and receiving a faculty appointment at the University of Texas Southwestern Medical School. While in Dallas, he worked extensively with Drs. Joseph L. Goldstein and Michael Brown, winners of the Nobel Prize in Medicine in 1985 for their work on cholesterol metabolism. In 1991, Dr. Luskey joined Scios, Inc. (now a member of the Johnson & Johnson family of companies) where he led research efforts to develop new treatments for diabetes and obesity. Subsequently, Dr. Luskey joined Metabolex, Inc. where he led research and drug development programs focused on diabetes and impaired glucose tolerance as Vice President, Clinical Development. Dr. Luskey also was head of experimental medicine for Tularik Inc. (subsequently acquired by Amgen Inc.), and was most recently head of preclinical and translational medicine for Nuvelo, Inc. Dr. Luskey received his medical education at the University of Texas Southwestern Medical School in Dallas. He trained in in
'/>"/>

SOURCE Intarcia Therapeutics, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Cell Therapeutics, Inc. Announces Reverse Stock Split
2. Cell Therapeutics, Inc.s Second Quarter 2008 Financial Results
3. Nile Therapeutics, Inc. Reports 2008 Second Quarter Financial Results
4. Zenobia Therapeutics, Inc. Receives Michael J. Fox Foundation for Parkinsons Research Award for Work on PD-implicated Protein LRRK2
5. Cell Therapeutics, Inc. Announces Single Institutional Investor to Purchase $44.5 Million of Units Consisting of Senior Convertible Notes and Warrants
6. Zenobia Therapeutics, Inc. Begins Operations as a Fragment-Based Lead Discovery Company
7. Shareholders Approve All Matters Proposed by Cell Therapeutics, Inc. at Special Meeting in Lieu of Annual Meeting of Shareholders
8. Cell Therapeutics, Inc. Repays $11.0 million Balance of 2008 Convertible Debt
9. Cell Therapeutics, Inc. Special Meeting in Lieu of Annual Meeting of Shareholders Scheduled for Thursday, June 19, 2008
10. Cell Therapeutics, Inc. Announces Issuance of 2011 Convertible Senior Notes and Common Stock Warrants to a Single Institutional Investor
11. Anesiva and Transcription Factor Therapeutics, Inc. Announce Licensing Agreement for Development and Commercialization of NF-kappa B Clinical Program
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/24/2014)... MENLO PARK, Calif. , July 24, 2014 ... biotechnology company in the emerging field of regenerative ... live webcast of a presentation to investors on ... 1:30 p.m. PDT.  The presentation will include an ... pipeline. To access the webcast, visit http://www.ustream.tv/channel/asterias-biotherapeutics ...
(Date:7/24/2014)... Yung-Eun Sung has announced that they have developed ... which can be applied as high performance electrodes ... is both a group leader at the Center ... (IBS) and a professor at the Seoul National ... regards to the development of relative simplicity, scalablity, ...
(Date:7/24/2014)... to settle into equilibriuma state of unchanging balance ... of non-equilibrium conditions where new possibilities lie. Non-equilibrium ... such as temperature fluctuations, freezing and melting, or ... body temperature, airplanes to fly, and the Earth ... even though these conditions exist naturally and are ...
(Date:7/24/2014)... 2014 Your cell phone may ... lithium-ion battery storage capacity. , New research indicates ... model created at Lawrence Livermore National Laboratory ... how carbon components will perform as electrodes. , ... urgent need for higher-performance batteries. Several key characteristics ...
Breaking Biology Technology:Asterias Biotherapeutics Announces Live Investor Webcast 2Asterias Biotherapeutics Announces Live Investor Webcast 3Asterias Biotherapeutics Announces Live Investor Webcast 4New approach to form non-equilibrium structures 2Getting More Life out of Lithium-ion Batteries 2
... help of 14 satellites currently in orbit and the ... scientists have been able to observe the Earths environment ... the world. The use of remote sensing technology ... the most common and deadly infectious diseases today such ...
... Ind. - Researchers have developed a new modeling ... tool that could help industry perfect lab-on-a-chip technology ... monitoring. , The experimental devices represent a new ... detect specific "target molecules," which will allow the ...
... SHANGHAI, China, Jan. 3 /Xinhua-PRNewswire/ -- WuXi PharmaTech (NYSE:,WX), ... to announce today that it has promoted Mr. Edward ... Officer., Prior to joining WuXi PharmaTech in August ... Operating Officer at Tanox, Inc., a NASDAQ listed,company later ...
Cached Biology Technology:NASA technology helps predict and prevent future pandemic outbreaks 2Model is first to compare performance of 'biosensors' 2Model is first to compare performance of 'biosensors' 3WuXi PharmaTech (NYSE: WX) Promotes Edward Hu to COO 2
(Date:7/25/2014)... Ravi Birla, associate professor of biomedical engineering at ... textbook on tissue engineering and artificial organ development., ... a comprehensive guide to entering into the field ... and professor of biomedical engineering at UH, served ... said that while there are other published books ...
(Date:7/25/2014)... at the University of Adelaide has opened the way for ... powdery mildew. , In Australia, annual barley production is second ... mildew is one of the most important diseases of barley. ... discovered the composition of special growths on the cell walls ... into the leaf. , The research, by the ARC Centre ...
(Date:7/25/2014)... complex congenital central nervous system disease that is ... tubes during the embryonic phase. Many patients have ... and neurocognitive retardation. Such problems decrease the patients, ... at Ankara Physical Medicine and Rehabilitation Education and ... children with SB, using the Pediatric Evaluation of ...
Breaking Biology News(10 mins):University of Houston researcher publishes textbook on tissue engineering 2New hope for powdery mildew resistant barley 2
... a common parasitic infection can vary greatly from person to ... of three strains of the cat-borne parasite Toxoplasma gondii ... it invades. Past research suggests that the parasite, estimated ... exacerbate psychotic symptoms and schizophrenia in genetically predisposed people. ...
... relevant to the effects of a mother’s high-fat ... in her children. An animal study at ... high-fat, high-carbohydrate diet causes oxidative stress—an excess of ... obesity and diabetes. Feeding rats antioxidants before and ...
... researchers from universities across the United States will arrive ... talks with lawmakers and their staffs about how to ... fuel the pursuit for medical breakthroughs in a time ... students participating in Hill Day, a twice-annual event sponsored ...
Cached Biology News:Toxoplasmosis: The strain explains severity of infection 2Antioxidants in pregnancy prevent obesity in animal offspring 2Young scientists to make the case for research funding on Capitol Hill 2Young scientists to make the case for research funding on Capitol Hill 3Young scientists to make the case for research funding on Capitol Hill 4
Request Info...
Mouse monoclonal [B314.1 (MAC 387)] to Macrophage L1 protein Calprotectin (rating: ****) ( Abpromise for all tested applications)....
Human/Mouse/Rat AMPK beta 1 Affinity Purified Polyclonal Ab...
Immunogen: Tissue / cell preparation. (Murine EHS laminin preparation) Storage: -20 C, Avoid Freeze/Thaw Cycles...
Biology Products: